$19.36
3.36% today
Nasdaq, Feb 05, 04:17 pm CET
ISIN
US0042251084
Symbol
ACAD
Sector
Industry

ACADIA Pharmaceuticals Inc. Stock price

$18.73
+1.27 7.27% 1M
+0.32 1.74% 6M
+0.38 2.07% YTD
-6.37 25.38% 1Y
-4.87 20.64% 3Y
-22.94 55.05% 5Y
-12.63 40.27% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.22 1.19%
ISIN
US0042251084
Symbol
ACAD
Sector
Industry

Key metrics

Market capitalization $3.12b
Enterprise Value $2.60b
P/E (TTM) P/E ratio 24.25
EV/FCF (TTM) EV/FCF 12.83
EV/Sales (TTM) EV/Sales 2.80
P/S ratio (TTM) P/S ratio 3.35
P/B ratio (TTM) P/B ratio 5.40
Revenue growth (TTM) Revenue growth 47.06%
Revenue (TTM) Revenue $929.24m
EBIT (operating result TTM) EBIT $112.24m
Free Cash Flow (TTM) Free Cash Flow $202.66m
Cash position $565.33m
EPS (TTM) EPS $0.77
P/E forward 25.96
P/S forward 3.21
EV/Sales forward 2.68
Short interest 13.89%
Show more

Is ACADIA Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

ACADIA Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:

12x Buy
63%
6x Hold
32%
1x Sell
5%

Analyst Opinions

19 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:

Buy
63%
Hold
32%
Sell
5%

Financial data from ACADIA Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
929 929
47% 47%
100%
- Direct Costs 78 78
198% 198%
8%
851 851
41% 41%
92%
- Selling and Administrative Expenses 458 458
16% 16%
49%
- Research and Development Expense 269 269
25% 25%
29%
125 125
183% 183%
13%
- Depreciation and Amortization 12 12
177% 177%
1%
EBIT (Operating Income) EBIT 112 112
173% 173%
12%
Net Profit 129 129
186% 186%
14%

In millions USD.

Don't miss a Thing! We will send you all news about ACADIA Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ACADIA Pharmaceuticals Inc. Stock News

Neutral
Business Wire
19 days ago
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on January 13, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 23,782 shares of common stock and 13,928 restricted stock units (“RSUs”) to twelve new employees under Acadia's 2024 Inducement ...
Neutral
Business Wire
22 days ago
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's CNS and rare disease drug candidates, which will be discussed today during a presentation by Catherine Owen Adams, Chief Executive Officer, at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. “2025 is shaping up to be an exciting y...
Neutral
Business Wire
22 days ago
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. If granted marketing authorization, trofinetide will be the first and only approved ...
More ACADIA Pharmaceuticals Inc. News

Company Profile

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Head office United States
CEO Catherine Adams
Employees 598
Founded 1993
Website www.acadia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today